Cargando…

Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study

BACKGROUND: Addition of trastuzumab to first-line palliative chemotherapy in gastroesophageal cancer patients with HER2 overexpression has shown to improve survival. Real-world data on HER2 assessment and administration of trastuzumab are lacking. The aim of this study was to assess HER2 testing, tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dijksterhuis, Willemieke P. M., Verhoeven, Rob H. A., Meijer, Sybren L., Slingerland, Marije, Haj Mohammad, Nadia, de Vos-Geelen, Judith, Beerepoot, Laurens V., van Voorthuizen, Theo, Creemers, Geert-Jan, van Oijen, Martijn G. H., van Laarhoven, Hanneke W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305095/ https://www.ncbi.nlm.nih.gov/pubmed/31927675 http://dx.doi.org/10.1007/s10120-020-01039-7

Ejemplares similares

Heterogeneity of first‐line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real‐world evidence study
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

Gender Differences in Treatment Allocation and Survival of Advanced Gastroesophageal Cancer: A Population-Based Study
por: Dijksterhuis, Willemieke P M, et al.
Publicado: (2021)

A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)
por: Stroes, Charlotte I, et al.
Publicado: (2022)

Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study
por: Pape, Marieke, et al.
Publicado: (2023)

SOURCE beyond first‐line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first‐line palliative systemic therapy
por: Kuijper, Steven C., et al.
Publicado: (2022)

A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577
por: Pape, Marieke, et al.
Publicado: (2022)

Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

A population-based study in synchronous versus metachronous metastatic esophagogastric adenocarcinoma
por: Pape, Marieke, et al.
Publicado: (2022)

Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer
por: van Velzen, Merel J. M., et al.
Publicado: (2022)

Long-term health-related quality of life in patients with advanced esophagogastric cancer receiving first-line systemic therapy
por: Pape, Marieke, et al.
Publicado: (2023)

Use of Palliative Chemotherapy and ICU Admissions in Gastric and Esophageal Cancer Patients in the Last Phase of Life: A Nationwide Observational Study
por: Besseling, Joost, et al.
Publicado: (2021)

The dynamics of HER2 status in esophageal adenocarcinoma
por: Creemers, Aafke, et al.
Publicado: (2018)

From presentation to paper: Gender disparities in oncological research
por: Dijksterhuis, Willemieke P.M., et al.
Publicado: (2019)

Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study
por: Mokadem, I., et al.
Publicado: (2019)

Cachexia, dietetic consultation, and survival in patients with pancreatic and periampullary cancer: A multicenter cohort study
por: Latenstein, Anouk E. J., et al.
Publicado: (2020)

The Use of (Network) Meta-Analysis in Clinical Oncology
por: ter Veer, Emil, et al.
Publicado: (2019)

Emerging targets in gastroesophageal adenocarcinoma: what the future looks like
por: Petrillo, Angelica, et al.
Publicado: (2023)

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas
por: Creemers, Aafke, et al.
Publicado: (2018)

The fear of cancer recurrence and progression in patients with pancreatic cancer
por: Pijnappel, Esther N., et al.
Publicado: (2022)

Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study
por: van Kleef, J. J., et al.
Publicado: (2021)

Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review
por: ter Veer, Emil, et al.
Publicado: (2018)

The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2016)

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis
por: Creemers, A., et al.
Publicado: (2017)

Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
por: ter Veer, Emil, et al.
Publicado: (2016)

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2017)

Online follow-up of individuals with gastroesophageal reflux disease using a patient-reported outcomes instrument: results of an observational study
por: Tielemans, Merel M, et al.
Publicado: (2013)

Population-based study of treatment and outcome of recurrent oesophageal or junctional cancer
por: Pape, Marieke, et al.
Publicado: (2022)

Open Access Capture of Patients With Gastroesophageal Reflux Disease Using an Online Patient-Reported Outcomes Instrument
por: Tielemans, Merel M, et al.
Publicado: (2012)

Incidence, Stage, Treatment, and Survival of Noncardia Gastric Cancer
por: van Velzen, Merel J. M., et al.
Publicado: (2023)

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
por: Schokker, Sandor, et al.
Publicado: (2019)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

Trends in treatment and overall survival among patients with proximal esophageal cancer
por: de Vos-Geelen, Judith, et al.
Publicado: (2019)

Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population‐based study
por: Pape, Marieke, et al.
Publicado: (2022)

Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis
por: Augustinus, Simone, et al.
Publicado: (2023)

Tumor‐immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas
por: Soeratram, Tanya TD, et al.
Publicado: (2021)

Methotrexate plus or minus cetuximab as first‐line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib‐randomized phase II study Commence
por: Ham, Janneke C., et al.
Publicado: (2020)

A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX
por: Stroes, Charlotte I., et al.
Publicado: (2021)

The association between wearable activity monitor metrics and performance status in oncology: a systematic review
por: Kos, Milan, et al.
Publicado: (2021)

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
por: Anderegg, M. C. J., et al.
Publicado: (2017)

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis
por: Haj Mohammad, N., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s5ualgnof8d14igsttrbcsukiv